GLMD

Galmed Pharmaceuticals Ltd. (GLMD) ESG Analysis Analysis (2026)

Invetso Score: 5.4/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.0 (Moderate)

GLMD’s environmental profile appears limited by the absence of disclosed emissions, energy, and waste metrics, leaving peer-relative performance difficult to verify versus better-reporting healthcare peers.

Zero reported R&D intensity in the provided metrics suggests a constrained innovation footprint, which can reduce exposure to resource-intensive development activities relative to research-heavy peers.

No evidence of environmental controversies is provided, but the lack of transparent sustainability disclosure weakens comparability against peers with more complete climate and resource reporting.

Given the company’s small leverage footprint, environmental liabilities appear unlikely to be structurally amplified by balance-sheet stress, unlike more indebted peers with less flexibility.

Social

Score:

The provided data do not show workforce, patient-safety, or product-responsibility indicators, so GLMD cannot be assessed as favorably as peers with stronger social disclosure.

Zero stock-based compensation to revenue may indicate lower dilution-related employee alignment concerns, but it does not substitute for evidence of stronger retention or culture versus peers.

No social controversies are indicated in the supplied information, yet the absence of disclosed metrics limits confidence that GLMD is outperforming peers on labor or stakeholder management.

As a healthcare company, social materiality is high, and GLMD’s limited disclosure leaves it positioned around peer average rather than clearly advantaged.

Governance

Score:

Very low debt-to-equity and net debt-to-EBITDA suggest conservative capital structure, which can reduce creditor pressure and governance risk relative to more leveraged peers.

Zero stock-based compensation to revenue may indicate less reliance on equity incentives, but the absence of board, audit, and ownership data prevents a stronger peer-relative governance assessment.

No filing-based evidence of governance controversies is provided, yet the sparse disclosure profile weakens transparency versus peers with more detailed governance reporting.

Overall governance appears somewhat supported by balance-sheet discipline, but limited disclosure keeps GLMD from ranking clearly above peers.

Overall Score

Score:

GLMD’s ESG positioning is broadly peer-average because low leverage supports governance resilience, but sparse disclosure prevents a stronger relative assessment across material ESG factors.

Score Driver: Limited ESG Disclosure Versus Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Galmed Pharmaceuticals Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →